Novavax Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has inked a license agreement with Serum Institute of India Private Limited (SIIPL) for the development and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in low- and middle-income countries (LMIC) and India.   This agreement excludes major upper-middle and high-income countries, for which Novavax continues to retain rights. NVX‑CoV2373 is a stable, prefus...